Greenleaf Trust Acquires 86 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Greenleaf Trust grew its position in IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 2.8% in the second quarter, HoldingsChannel.com reports. The firm owned 3,119 shares of the medical research company’s stock after acquiring an additional 86 shares during the period. Greenleaf Trust’s holdings in IQVIA were worth $677,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Pitcairn Co. boosted its position in shares of IQVIA by 101.8% in the first quarter. Pitcairn Co. now owns 2,226 shares of the medical research company’s stock worth $515,000 after purchasing an additional 1,123 shares during the period. Raymond James & Associates boosted its position in shares of IQVIA by 4.1% in the first quarter. Raymond James & Associates now owns 729,957 shares of the medical research company’s stock worth $168,773,000 after purchasing an additional 28,899 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of IQVIA by 205.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 14,162 shares of the medical research company’s stock worth $3,074,000 after purchasing an additional 9,522 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of IQVIA in the first quarter worth $599,000. Finally, Verition Fund Management LLC purchased a new position in shares of IQVIA in the first quarter worth $258,000. 86.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup downgraded shares of IQVIA from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $275.00 to $245.00 in a report on Thursday, November 17th. Morgan Stanley lowered their target price on shares of IQVIA from $260.00 to $240.00 and set an “overweight” rating on the stock in a report on Thursday, October 27th. Robert W. Baird boosted their target price on shares of IQVIA to $266.00 in a report on Thursday, October 27th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of IQVIA from $290.00 to $270.00 in a report on Tuesday, October 18th. Finally, Argus boosted their target price on shares of IQVIA from $260.00 to $275.00 in a report on Thursday, August 18th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $257.57.

IQVIA Trading Up 0.8 %

Shares of IQV opened at $217.72 on Thursday. IQVIA Holdings Inc. has a twelve month low of $165.75 and a twelve month high of $285.61. The company has a market cap of $40.44 billion, a P/E ratio of 35.46, a P/E/G ratio of 2.06 and a beta of 1.37. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 2.29. The company’s fifty day simple moving average is $196.79 and its 200-day simple moving average is $210.49.

About IQVIA

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm’s life science clients.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVGet Rating).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.